CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces filing for insolvency1 and requesting to be placed in receivership2 to the Versailles Economic Affairs Court3, as well as the suspension of CARMAT shares trading, starting June 30, 2025, before stock market opening.
Insolvency filing and request to be placed in receivership
On June 20, 2025, CARMAT announced in a press release being at risk of insolvency as early as the end of June 2025 unless managing before then, to secure additional cash of at least…